F
actor VIII (FVIII), a protein heavily involved in clot formation, is biochemically stabilized in plasma by von Willebrand Factor (vWF). The FVIII-vWF complex supports FVIII binding and cleavage with other components of the coagulation cascade and mediates platelet attachment to damaged subendothelium. 1 A relationship between levels of FVIII and vWF has been demonstrated. 2, 3 Several studies support the association between elevation in either FVIII or vWF and increased risk of venous thrombosis and recurrent thromboembolic events. [4] [5] [6] [7] Elevated FVIII is a risk factor for acute ischemic stroke (AIS) and coronary artery disease. 4, 8, 9 However, no evidence exists for the combined effect of FVIII and vWF in the context of AIS. In this study, we sought to determine differences in stroke severity, in-hospital complications, and outcomes between patients with normal serum values of FVIII and vWF and those with singular elevation in FVIII or combined elevation in both FVIII and vWF. In addition, we explored the relationship of singular elevation in vWF with these variables.
Methods
Patients who presented to our stroke center with AIS between July 2008 and October 2013 were identified consecutively from our prospective registry. Patients <18 years or who did not have FVIII and vWF levels obtained during admission were excluded.
Laboratory tests for hypercoagulability were ordered at the discretion of the treating physician, typically when no obvious cause of stroke was identified. The laboratory reference range for both FVIII and vWF is 50% to 150%. We defined elevated levels at the 200% threshold based on our previous research. 4 Patients were divided into 4 groups: both FVIII and vWF within normal range (FVIII−/vWF−); FVIII within normal range, but elevated vWF (FVIII−/vWF+); elevated FVIII, but normal vWF (FVIII+/ vWF−); and elevation of both FVIII and vWF (FVIII+/vWF+). Appropriate statistical tests and multivariate logistic regression analyses were conducted, including adjustment for age, National Institute of Health Stroke Scale (NIHSS), glucose level on admission, and administration of intravenous tissue-type plasminogen activator. Our institutional review board approved this study.
Background and

Results
Patient Demographics and Baseline Characteristics
Among 1453 AIS cases, 148 patients met criteria; 62 patients (41.9%) had FVIII−/vWF−, 19 patients (12.8%) had FVIII−/ Table 1 . 
FVIII+/vWF+ Compared With FVIII−/vWF−
Discussion
Our study is the first to examine the relationship between FVIII and vWF with respect to patient characteristics and outcomes in the setting of AIS. Almost half of our sample had either elevated FVIII or vWF, and over one third had concurrent elevation, suggesting that elevation in these factors is not rare among patients with AIS and merits exploration.
Groups of patients with FVIII+, regardless of vWF, had elevated erythrocyte sedimentation rate and C-reactive protein compared with those in the FVIII−/vWF− group, suggesting that FVIII may be driving this association and supporting elevation in FVIII as an acute phase response. 4 Given that the FVIII−/vWF+ group was not associated with higher inflammatory markers, but was associated with worse outcomes, the results suggest that vWF elevation is clinically relevant, independent of inflammation.
Patients in the FVIII+/vWF+ group experienced recurrent thrombotic events and neuroworsening with significantly greater frequency. Isolated FVIII+ is associated with patient baseline characteristics and may be related to stroke onset and the acute phase of stroke. Groups of patients with vWF+, regardless of FVIII, had higher median discharge modified Rankin Scale scores. Taken together, our results suggest that elevation of FVIII and vWF relate to different stages of AIS progression. Combined elevation of FVIII and vWF seems to be related to in-hospital events, suggesting a cooperative effect on AIS progression. This study is limited by single measurement of FVIII/ vWF, cross-sectional design, and relatively small sample size. Testing of FVIII/vWF was not random or universal, which likely results in selection bias and limits generalizability. Our results require validation in a prospective study using serial measurements to determine whether concurrent FVIII/vWF elevation is related exclusively to the acute phase of stroke or is more broadly related to both stroke risk and recovery.
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